News
Boehringer gets FDA's second 'national priority' approval
Boehringer Ingelheim's lung cancer drug Hernexeos has become the second medicine approved after an FDA national priority review.
News
Generate's IPO gets over the line, raising $400m
AI-powered drug developer Generate Biomedicine completes a $400m IPO, the largest for biotech on the Nasdaq so far this year.
News
Eisai unveils digital platform for kidney cancer patients
Eisai has launched a 'digital destination', called Kompass, that aims to support patients after they have been given a diagnosis of kidney cancer.
Oncology
Sponsored
Collaboration & personalisation in rare disease R&D, with AO...
For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.
News
Astellas bets on Vir cancer drug, and other licensing deals
Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
